Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

NCT05548075 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-01-19

No results posted yet for this study

Summary

The purpose of this study is to assess brain activity under Psilocybin in a cohort of people with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

Psilocybin

Up to 25mg of Psilocybin on 2 occasions.

BEHAVIORAL

Therapeutic support

Psychological and physical therapeutic support

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • David Nutt · Imperial College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-15
Primary Completion
2024-01-10
Completion
2024-07-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05548075 on ClinicalTrials.gov